Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (361)	8/8/2005 4:44:29 PM
From: tuck	Read Replies (1) \| Respond to of 510

CIPH hits revenue, misses a bit on earnings. Restructuring confirmed. Matt Hogan looking for the exit? Don't know this Acosta fellow; will have to track down his alleged track record. Loss was 31 cents versus consensus of 27. Estimate for revenue was $7.6 million. >>FREMONT, Calif., Aug. 8 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) today announced financial results for the second quarter ended June 30, 2005. Ciphergen's total revenue was $7.5 million in the second quarter of 2005 as compared to $8.3 million in the second quarter of 2004. Ciphergen's net loss was $9.0 million in the second quarter of 2005 as compared to $13.1 million in the second quarter of 2004. As of June 30, 2005, the Company's cash and investments were $23.5 million. Total long term debt totaled $28.4 million, of which $28.3 million was convertible debt. On July 22, Ciphergen entered into a strategic alliance with Quest Diagnostics whereby Quest Diagnostics made a $15 million equity investment in Ciphergen and has agreed to lend Ciphergen $10 million to fund certain development activities; this loan will be forgiven if certain milestones are made. The Company also announced an increased focus on its emerging proteomic biomarker-based clinical diagnostic business, for which a strategic alliance was recently formed with Quest Diagnostics. The Company believes that it has unique capabilities to discover proteomic biomarkers that can be translated into highly predictive research and clinical diagnostic assays that enable improved understanding of disease pathology, faster pharmacoproteomic-based drug development and the improvement of patient care. "The recently announced alliance with Quest Diagnostics is an important step towards translating our proprietary biomarker discovery and assay capabilities into commercial clinical diagnostic tests to address unmet medical needs and improve patient care," stated William E. Rich, CEO. "I am pleased to announce the promotion of Gail S. Page to President and COO. Under her leadership, we are integrating and streamlining our operating divisions to focus our resources on biomarker discovery partnerships with key academic and pharmaceutical customers to speed development of diagnostic and theranostic assays and better leverage the Quest alliance." Ciphergen also announced that it intends to focus its sales efforts on collaborative BDC service projects with key translational research customers in academia and pharma. The Company believes that this increased emphasis on project-scale, collaborative services will expedite the success of its customers with the technology, increase ProteinChip® product and service revenues, while also enabling the Company to reduce its operating expenses. In line with this strategy, a number of organizational changes were implemented at the Company, including steps to reduce headcount by approximately 20% by the fourth quarter. In addition Ciphergen is integrating its divisions into one organization and has promoted Gail S. Page to President and Chief Operating Officer of Ciphergen. Other Recent Highlights * Major presence at AACR Annual Meeting. At the American Association of Cancer Research (AACR) annual conference, there were a total of 44 studies presented that utilized Ciphergen's ProteinChip technology for biomarker discovery, validation, identification and assay development across a wide varieties of cancers and therapeutic strategies. At a special invited session, Dr. Judah Folkman of the Children's Hospital Boston presented results of work done in his laboratory and in collaboration with Ciphergen scientists using SELDI-TOF-MS, suggesting that proteomic analysis of circulating platelets can potentially be useful for early cancer diagnosis. * Promising results presented at AUA Annual Meeting. Dr. Daniel W. Chan and Dr. Zhen Zhang of the Johns Hopkins Medical School, working in collaboration with Ciphergen scientists, presented results at the American Urological Association Annual Meeting suggesting that two protein markers, in combination with PSA levels, may be useful in predicting risk of recurrence within five years of treatment. * Agreement signed with National Cancer Institute. In April, Ciphergen signed a material transfer agreement with the NCI Clinical Proteomics Reference Laboratory (CPRL) which allows CPRL to evaluate the ProteinChip System, Series 4000, arrays and software to study biomarker patterns indicative of ovarian cancer. The CPRL intends to test archived ovarian cancer samples on assays it has constructed on Ciphergen's platform. * Novel Approach Reported to Detect Cancer by Measuring Host Response Proteins. A Ciphergen study performed in collaboration with scientists at the Johns Hopkins University School of Medicine was published in the International Journal of Cancer which suggested a novel alternative to searching for highly specific classical markers coming directly from tumors. This approach utilizes SELDI-TOF-MS to detect and quantitatively assay for post-translationally modified proteins formed by the host response to the tumor. * Introduction of Deep Proteome(TM) Research Services. At the American Society of Mass Spectrometry Annual Meeting, Ciphergen announced the introduction of Deep Proteome Research Services through our Biomarker Discovery Center® (BDC) scientists, making proprietary Equalizer(TM) protein biomarker discovery technology available to scientists for the first time. Deep Proteome Research Services enable scientists to look at low abundance proteins in various biological samples and significantly improve their biomarker discovery power. These services are preferentially provided to Ciphergen's ProteinChip System customers and BDC collaboration partnerships. * Biomarker Research Collaboration with Bayer Pharmaceuticals. Ciphergen will analyze patient samples from one of Bayer's compounds in a Phase II clinical trial in cancer, with a goal of delivering to Bayer a biomarker assay that is predictive of drug response. This agreement expands Ciphergen's business initiative to form pharmacoproteomic collaborations with pharmaceutical companies to accelerate and streamline clinical development of new drugs through the identification of important biomarkers of drug response. * Patent Issuances. Ciphergen has had seven patents issue in the U.S. during the first half of 2005; of particular interest, one issued patent is directed to the detection of multiple diagnostic markers by SELDI-TOF-MS for the diagnosis of disease, and another is directed toward methods of using SELDI-TOF-MS to rapidly purify proteins for applications including protein identification. Ciphergen currently has 28 issued patents and 109 active patent families. * Other Management Changes. James S. Burns, President and CEO of EntreMed, Inc. has joined Ciphergen's Board of Directors. Mr. Burns brings to Ciphergen significant experience and accomplishments in both the pharmaceutical and laboratory products industries, particularly important to the Company's initiatives to further penetrate the pharmaceutical industry. Matthew Hogan, the Company's Chief Financial Officer, has informed the Company that he is considering pursuing potential alternative career opportunities in the investment management field. He currently remains as the Chief Financial Officer of the Company and has made no decision to leave the Company at this time. In addition, Michael Acosta recently joined Ciphergen as Vice President, Quality Assurance/Regulatory Affairs. Mr. Acosta has a long record of ensuring compliance with regulatory requirements and his primary initial focus at the Company will in the area of cGMP compliance to facilitate the Company's biomarker diagnostic development program.<< snip Cheers, Tuck